RXi Pharmaceuticals Stock Price, News & Analysis (NASDAQ:RXII) Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.88▼$1.0250-Day Range$0.36▼$0.5052-Week Range$0.31▼$7.70Volume478,691 shsAverage Volume1.73 million shsMarket Capitalization$4.08 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsHeadlinesSocial MediaStock AnalysisCompetitorsHeadlinesSocial Media About RXi Pharmaceuticals Stock (NASDAQ:RXII)Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics that addresses unmet medical needs. Its clinical product candidate includes RXI-109, an RNAi compound developed for the reduction of dermal scarring in planned surgeries. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.Read More RXII Stock News HeadlinesOctober 26, 2023 | finance.yahoo.comRex International Holding Ltd (RXI.SG)April 19, 2023 | thestreet.comGalena's Breast Cancer Vaccine Doomed to FailDecember 9, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.March 20, 2023 | finance.yahoo.comQ4 2022 Catalyst Pharmaceuticals Inc Earnings CallSeptember 30, 2022 | finance.yahoo.comiShares Global Consumer Discretionary ETF (RXI)October 18, 2020 | markets.businessinsider.comRXi Pharmaceuticals CHARTJune 6, 2020 | www.bloomberg.comRXi Pharmaceuticals Reports Third Quarter 2018 Financial Results and Recent Corporate HighlightsMarch 25, 2020 | www.fool.comRXi Pharmaceuticals (RXII) - Income StatementDecember 9, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comFebruary 7, 2020 | www.bloomberg.comRXi Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Recent Corporate HighlightsDecember 1, 2019 | www.thestreet.com7 Firms Developing RNAi DrugsFebruary 15, 2019 | finance.yahoo.comPhio Pharmaceuticals Appoints Gerrit Dispersyn as New Chief Executive Officer Effective March 1See More Headlines Receive RXII Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RXi Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2018Today12/09/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical Preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RXII CUSIPN/A CIK1533040 Webwww.rxipharma.com Phone(508) 767-3861FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,450,000.00 Net Margins-4,990.20% Pretax MarginN/A Return on Equity-412.15% Return on Assets-179.54% Debt Debt-to-Equity RatioN/A Current Ratio1.77 Quick Ratio1.77 Sales & Book Value Annual Sales$10,000.00 Price / Sales408.39 Cash FlowN/A Price / Cash FlowN/A Book Value$0.77 per share Price / Book1.21Miscellaneous Outstanding Shares4,380,000Free FloatN/AMarket Cap$4.08 million OptionableNot Optionable Beta2.07 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesGerrit DispersynPresident, Chief Executive Officer & DirectorJames CardiaVice President-Business OperationsCaitlin KontulisSecretary, VP-Finance & AdministrationSimon FrickerVice President-ResearchKey CompetitorsMonopar TherapeuticsNASDAQ:MNPRCingulateNASDAQ:CINGAddex TherapeuticsNASDAQ:ADXNVirpax PharmaceuticalsNASDAQ:VRPXBlue Water BiotechNASDAQ:BWVView All Competitors RXII Stock Analysis - Frequently Asked Questions How were RXi Pharmaceuticals' earnings last quarter? RXi Pharmaceuticals Co. (NASDAQ:RXII) posted its earnings results on Tuesday, August, 14th. The biotechnology company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.16. The biotechnology company had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.02 million. RXi Pharmaceuticals had a negative net margin of 4,990.20% and a negative trailing twelve-month return on equity of 412.15%. When did RXi Pharmaceuticals' stock split? RXi Pharmaceuticals's stock reverse split before market open on Monday, January 8th 2018. The 1-10 reverse split was announced on Friday, January 5th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 5th 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of RXi Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other RXi Pharmaceuticals investors own include Rigel Pharmaceuticals (RIGL), Novavax (NVAX), Auris Medical (EARS), Endologix (ELGX), Idera Pharmaceuticals (IDRA), Synergy Pharmaceuticals (SGYP), Anavex Life Sciences (AVXL), Micron Technology (MU) and This page (NASDAQ:RXII) was last updated on 12/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RXi Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.